ADA-话题@MedSci

#ADA#

386篇内容 | 3201人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1264777, encodeId=4f681264e775a, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Clin Cancer Res：Wee1抑制剂Adavosertib(AZD1775)在晚期实体肿瘤患者中的抗肿瘤活性及相关生物标志物, objectType=article, longId=214645, objectId=1284214645f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1284214645f5, replyNumber=0, likeNumber=32, createdTime=2021-07-24, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1284214645f5, moduleTitle=Clin Cancer Res：Wee1抑制剂Adavosertib(AZD1775)在晚期实体肿瘤患者中的抗肿瘤活性及相关生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1284214645f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264776, encodeId=24cd1264e7652, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=2021ADA热点｜新一代基础胰岛素，『甘精胰岛素U300』多项重磅研究备受关注！, objectType=article, longId=213139, objectId=5dfb213139e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5dfb213139e5, replyNumber=0, likeNumber=32, createdTime=2021-06-25, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5dfb213139e5, moduleTitle=2021ADA热点｜新一代基础胰岛素，『甘精胰岛素U300』多项重磅研究备受关注！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5dfb213139e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264775, encodeId=7f361264e755f, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Blood：腺苷脱氨酶重度联合免疫缺陷(ADA SCID)患者基因治疗后的长期预后, objectType=article, longId=212666, objectId=66fb2126667e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66fb2126667e, replyNumber=0, likeNumber=45, createdTime=2021-06-14, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66fb2126667e, moduleTitle=Blood：腺苷脱氨酶重度联合免疫缺陷(ADA SCID)患者基因治疗后的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66fb2126667e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264774, encodeId=4c9d1264e7490, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=J Headache Pain：依普奈珠单抗预防慢性偏头痛的有效性和安全性：PROMISE-2 III期研究结果, objectType=article, longId=212452, objectId=42a3212452e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42a3212452e6, replyNumber=0, likeNumber=39, createdTime=2021-06-09, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42a3212452e6, moduleTitle=J Headache Pain：依普奈珠单抗预防慢性偏头痛的有效性和安全性：PROMISE-2 III期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42a3212452e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264773, encodeId=af881264e730f, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=男性患者60岁，频发室早！心电图VI典型J点太高下邪行压低，典型1型Brugada图形，V2 导联，典型Brugada2型图形，是否能考虑Brugada？如何处理？有无危险性！没有晕厥，无家族史。, objectType=article, longId=211805, objectId=bc1b211805d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc1b211805d3, replyNumber=0, likeNumber=43, createdTime=2021-05-27, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc1b211805d3, moduleTitle=男性患者60岁，频发室早！心电图VI典型J点太高下邪行压低，典型1型Brugada图形，V2 导联，典型Brugada2型图形，是否能考虑Brugada？如何处理？有无危险性！没有晕厥，无家族史。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc1b211805d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264772, encodeId=42221264e7231, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=brugada综合症发作室速应该怎么治疗？, objectType=article, longId=211766, objectId=df3f211e6694, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df3f211e6694, replyNumber=0, likeNumber=49, createdTime=2021-05-26, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df3f211e6694, moduleTitle=brugada综合症发作室速应该怎么治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df3f211e6694)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264771, encodeId=c7521264e71a6, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Allergy Asthma Clin Immunol：早期宠物暴露与ADAM33甲基化模式的交互作用对过敏性鼻炎的影响 , objectType=article, longId=211669, objectId=daeb211669e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=daeb211669e0, replyNumber=0, likeNumber=42, createdTime=2021-05-24, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=daeb211669e0, moduleTitle=Allergy Asthma Clin Immunol：早期宠物暴露与ADAM33甲基化模式的交互作用对过敏性鼻炎的影响 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=daeb211669e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264770, encodeId=bb211264e7014, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Lancet：每日1次Upadacitinib单药治疗可显著改善中重度特应性皮炎患者临床症状, objectType=article, longId=211663, objectId=c26d2116637e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c26d2116637e, replyNumber=0, likeNumber=29, createdTime=2021-05-24, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c26d2116637e, moduleTitle=Lancet：每日1次Upadacitinib单药治疗可显著改善中重度特应性皮炎患者临床症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c26d2116637e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264769, encodeId=6dfe1264e69ae, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=JAHA：Brugada综合征患者家庭成员心源性猝死的年龄重要吗？, objectType=article, longId=211605, objectId=d3ab21160518, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3ab21160518, replyNumber=0, likeNumber=41, createdTime=2021-05-22, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3ab21160518, moduleTitle=JAHA：Brugada综合征患者家庭成员心源性猝死的年龄重要吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3ab21160518)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264768, encodeId=d2d61264e6874, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=J Headache Pain：厄瑞努单抗可有效且安全的治疗难治性慢性偏头痛患者, objectType=article, longId=211445, objectId=447221144596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=447221144596, replyNumber=0, likeNumber=43, createdTime=2021-05-19, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=447221144596, moduleTitle=J Headache Pain：厄瑞努单抗可有效且安全的治疗难治性慢性偏头痛患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=447221144596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264767, encodeId=ceb91264e6705, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=NEJM：Vadadustat在透析或非透析依赖性慢性肾病患者中治疗贫血的作用, objectType=article, longId=210638, objectId=c4772106386e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4772106386e, replyNumber=0, likeNumber=33, createdTime=2021-05-01, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4772106386e, moduleTitle=NEJM：Vadadustat在透析或非透析依赖性慢性肾病患者中治疗贫血的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4772106386e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264766, encodeId=f7151264e66a4, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=NEJM：Upadacitinib治疗银屑病关节炎疗效优于阿达木单抗, objectType=article, longId=209559, objectId=afa5209559ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afa5209559ff, replyNumber=0, likeNumber=32, createdTime=2021-04-06, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afa5209559ff, moduleTitle=NEJM：Upadacitinib治疗银屑病关节炎疗效优于阿达木单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afa5209559ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264765, encodeId=9ea91264e65bb, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床, objectType=article, longId=207001, objectId=7c4620e00147, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c4620e00147, replyNumber=0, likeNumber=38, createdTime=2021-02-11, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c4620e00147, moduleTitle=ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c4620e00147)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264764, encodeId=f0ba1264e64fa, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=ADA：孕期这样运动才能更好降低妊娠期糖尿病风险, objectType=article, longId=206231, objectId=4a21206231fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a21206231fb, replyNumber=0, likeNumber=43, createdTime=2021-01-27, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a21206231fb, moduleTitle=ADA：孕期这样运动才能更好降低妊娠期糖尿病风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a21206231fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264763, encodeId=1bac1264e63a1, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=KRAS抑制剂Adagrasib与Sotorasib治疗肺癌对比, objectType=article, longId=205368, objectId=7c3220536802, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c3220536802, replyNumber=0, likeNumber=29, createdTime=2021-01-07, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c3220536802, moduleTitle=KRAS抑制剂Adagrasib与Sotorasib治疗肺癌对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c3220536802)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264762, encodeId=547e1264e6261, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=NICE拒绝了诺华的Adakveo（crizanlizumab）, objectType=article, longId=203864, objectId=69b5203864d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69b5203864d9, replyNumber=0, likeNumber=36, createdTime=2020-12-01, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69b5203864d9, moduleTitle=NICE拒绝了诺华的Adakveo（crizanlizumab）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69b5203864d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264761, encodeId=95821264e61bc, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=KRAS抑制剂adagrasib治疗非小细胞肺癌，83%应答患者无疾病进展, objectType=article, longId=202536, objectId=c48320253636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c48320253636, replyNumber=0, likeNumber=35, createdTime=2020-10-28, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c48320253636, moduleTitle=KRAS抑制剂adagrasib治疗非小细胞肺癌，83%应答患者无疾病进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c48320253636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264760, encodeId=9d471264e6078, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=NEJM：Upadacitinib治疗生物药难治性类风湿关节炎, objectType=article, longId=202158, objectId=6b4b202158b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b4b202158b8, replyNumber=0, likeNumber=40, createdTime=2020-10-17, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b4b202158b8, moduleTitle=NEJM：Upadacitinib治疗生物药难治性类风湿关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b4b202158b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264759, encodeId=d8701264e593a, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=J Clin Oncol：新型LSD1抑制剂Iadademstat单一治疗复发/难治性AML初露成效, objectType=article, longId=202153, objectId=31d82021531a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31d82021531a, replyNumber=0, likeNumber=34, createdTime=2020-10-17, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31d82021531a, moduleTitle=J Clin Oncol：新型LSD1抑制剂Iadademstat单一治疗复发/难治性AML初露成效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31d82021531a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264758, encodeId=2f7e1264e58e5, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=靶向ADAMTS5骨关节炎新型纳米抗体，默克以5000万欧元授予给诺华, objectType=article, longId=201991, objectId=5d832019917b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d832019917b, replyNumber=0, likeNumber=32, createdTime=2020-10-13, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d832019917b, moduleTitle=靶向ADAMTS5骨关节炎新型纳米抗体，默克以5000万欧元授予给诺华, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d832019917b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ADA

2020-05-29

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Clin Cancer Res：Wee1抑制剂Adavosertib(AZD1775)在晚期实体肿瘤患者中的抗肿瘤活性及相关生物标志物

2021-07-24

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

2021ADA热点｜新一代基础胰岛素，『甘精胰岛素U300』多项重磅研究备受关注！

2021-06-25

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Blood：腺苷脱氨酶重度联合免疫缺陷(ADA SCID)患者基因治疗后的长期预后

2021-06-14

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

J Headache Pain：依普奈珠单抗预防慢性偏头痛的有效性和安全性：PROMISE-2 III期研究结果

2021-06-09

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

男性患者60岁，频发室早！心电图VI典型J点太高下邪行压低，典型1型Brugada图形，V2 导联，典型Brugada2型图形，是否能考虑Brugada？如何处理？有无危险性！没有晕厥，无家族史。

2021-05-27

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

brugada综合症发作室速应该怎么治疗？

2021-05-26

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Allergy Asthma Clin Immunol：早期宠物暴露与ADAM33甲基化模式的交互作用对过敏性鼻炎的影响

2021-05-24

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Lancet：每日1次Upadacitinib单药治疗可显著改善中重度特应性皮炎患者临床症状

2021-05-24

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

JAHA：Brugada综合征患者家庭成员心源性猝死的年龄重要吗？

2021-05-22

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

J Headache Pain：厄瑞努单抗可有效且安全的治疗难治性慢性偏头痛患者

2021-05-19

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

NEJM：Vadadustat在透析或非透析依赖性慢性肾病患者中治疗贫血的作用

2021-05-01

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

NEJM：Upadacitinib治疗银屑病关节炎疗效优于阿达木单抗

2021-04-06

柳叶一刀 (审核中...)

前往app查看评论内容

#ADA#

ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床

2021-02-11

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

ADA：孕期这样运动才能更好降低妊娠期糖尿病风险

2021-01-27

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

KRAS抑制剂Adagrasib与Sotorasib治疗肺癌对比

2021-01-07

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

NICE拒绝了诺华的Adakveo（crizanlizumab）

2020-12-01

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

KRAS抑制剂adagrasib治疗非小细胞肺癌，83%应答患者无疾病进展

2020-10-28

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

NEJM：Upadacitinib治疗生物药难治性类风湿关节炎

2020-10-17

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

J Clin Oncol：新型LSD1抑制剂Iadademstat单一治疗复发/难治性AML初露成效

2020-10-17

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

靶向ADAMTS5骨关节炎新型纳米抗体，默克以5000万欧元授予给诺华

2020-10-13

科室
- - 订阅+
  - 更多科室
工具
服务